Juno Therapeutics (JUNO) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (1.26 million) in Juno Therapeutics (JUNO). On Wednesday, The value of composite uptick trades was $4.03 million, whereas, the value of composite downtick trades was $5.29 million and the ratio between the two was 0.76, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $2.07 million. The negative money flow of ($2.07 million) shows selling on strength. Juno Therapeutics (JUNO) gained $0.77 intraday at $28.24 and registrered 2.8% for the week.
Also, Barclays initiates coverage on Juno Therapeutics (NASDAQ:JUNO). The current rating of the shares is Equal-weight, according to the research report released by the firm. The brokerage firm announces the price target at $48 per share. The rating by the firm was issued on July 6, 2016.
Juno Therapeutics (NASDAQ:JUNO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $27.39 and $27.39 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $28.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $28.65, notching a gain of 4.30% for the day. The total traded volume was 1,997,063 . The stock had closed at $27.47 on the previous day.
The stock has recorded a 20-day Moving Average of 19.55% and the 50-Day Moving Average is 26.99%. In a related news, The Securities and Exchange Commission has divulged that Klausner Richard, director of Juno Therapeutics, Inc., had unloaded 12,000 shares at an average price of $40.71 in a transaction dated on June 24, 2016. The total value of the transaction was worth $488,520.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.